Meet Neal Akhave, M.D.
Neal S. Akhave, M.D.
Department of Thoracic-Head & Neck Med Onc, Division of Cancer Medicine
About Dr. Neal S. Akhave
Dr. Akhave graduated from the University of Missouri-Kansas City School of Medicine in 2013 (B.A., Liberal Arts) and 2014 (M.D.). He completed his internal medicine residency at Washington University/Barnes Jewish Hospital in St. Louis in 2017 and then participated in a post-doctoral research fellowship with Lukas Wartman, MD understanding the role of epigenetic modifiers in lung adenocarcinoma. He then completed his Hematology/Oncology fellowship at M.D. Anderson Cancer Center in 2022. In 2022, Dr. Akhave was appointed Assistant Professor in the Department of Thoracic/Head & Neck Medical Oncology. As a clinical investigator, Dr. Akhave designs and oversees clinical trials for a variety of head and neck malignancies with a particular focus in oral cavity tumors and rare skull base tumors, including those involving the anterior and lateral skull base. Dr. Akhave’s research includes identifying novel therapeutics and predictive biomarkers for patients with head and neck malignancies.
Present Title & Affiliation
Primary Appointment
Assistant Professor, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Assistant Professor, Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
2014 | University of Missouri - Kansas City School of Medicine, Missouri, KS, USA, MD, Medical Degree |
2014 | University of Missouri - Kansas City School of Medicine, Missouri, KS, USA, BA, Bachelor's Degree, Liberal Arts |
Postgraduate Training
2019-2022 | Clinical Fellowship, Hematology/Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX |
2017-2019 | Research Associate, Laboratory of Lukas Wartman, Division of Oncology, Section of Bone Marrow Transplant, Washington University School of Medicine, St. Louis, MO |
2014-2017 | Residency, Internal Medicine, Barnes Jewish Hospital/Washington University School of Medicine, St. Louis, MO |
Board Certifications
2017 | American Board of Internal Medicine |
Experience & Service
Other Appointments/Responsibilities
Oncology Chief Fellow, The University of Texas MD Anderson Cancer Center Hematology, Houston, TX, 2021 - 2022
Internal Medicine Hospitalist, Washington University School of Medicine, St. Louis, MO, 2017 - 2019
Honors & Awards
2014 | Gold Humanism Honor Society, University of Missouri-Kansas City School of Medicine |
2013 | Alpha Omega Alpha, University of Missouri-Kansas City School of Medicine |
Professional Memberships
Selected Publications
Peer-Reviewed Articles
- Akhave NS, Biter AB, Hong DS. The Next Generation of KRAS Targeting: Reasons for Excitement and Concern. Mol Cancer Ther 21(11):1645-1651, 2022. PMID: 36282862.
- Akhave N, Zhang J, Bayley E, Frank M, Chiou SH, Behrens C, Chen R, Hu X, Parra ER, Lee WC, Swisher S, Solis L, Weissferdt A, Moran C, Kalhor N, Zhang J, Scheet P, Vaporciyan AA, Sepesi B, Gibbons DL, Heymach JV, Lee JJ, Wistuba II, Andrew Futreal P, Zhang J, Fujimoto J, Reuben A. Immunogenomic Profiling of Lung Adenocarcinoma Reveals Poorly Differentiated Tumors are Associated with an Immunogenic Tumor Microenvironment. Lung Cancer 172:19-28, 2022. e-Pub 2022. PMID: 35973335.
- Schmidt ST, Akhave N, Knightly RE, Reuben A, Vokes N, Zhang J, Li J, Fujimoto J, Byers LA, Sanchez-Espiridion B, Diao L, Wang J, Federico L, Forget MA, McGrail DJ, Weissferdt A, Lin SY, Lee Y, Suzuki E, Kovacs JJ, Behrens C, Wistuba II, Futreal A, Vaporciyan A, Sepesi B, Heymach JV, Bernatchez C, Haymaker C, Cascone T, Zhang J, Bristow CA, Heffernan TP, Negrao MV, Gibbons DL, ICON Team. Shared Nearest Neighbors Approach and Interactive Browser for Network Analysis of a Comprehensive Non-Small-Cell Lung Cancer Data Set. JCO Clin Cancer Inform 6:e2200040, 2022. PMID: 35944232.
- Akhave NS, Biter AB, Hong DS. Mechanisms of Resistance to KRASG12C-Targeted Therapy. Cancer Discov 11(6):1345-1352, 2021. e-Pub 2021. PMID: 33820777.
- Paul S, Jammal N, Akhave N, Aung PP, Loghavi S, Jain N, Garcia-Manero G, Borthakur G, Verstovsek S, Jabbour E, Adachi J, Masarova L, Daver N, Ravandi F, Pemmaraju N. Atypical Cases of Necrotizing Sweet Syndrome in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia. Br J Haematol 191(1):e10-e13, 2020. e-Pub 2020. PMID: 32686139.